AXGN Key Statistics, Chart & Performance
The current stock price of AXGN is 33.45 USD. In the past month the price increased by 16.75%. In the past year, price increased by 107.64%.
AXGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.96 | 216.61B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.83 | 203.98B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.46 | 141.96B | ||
| SYK | STRYKER CORP | 26.77 | 134.80B | ||
| BDX | BECTON DICKINSON AND CO | 13.53 | 55.70B | ||
| IDXX | IDEXX LABORATORIES INC | 54.55 | 54.93B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.83 | 50.45B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.12 | 37.88B | ||
| RMD | RESMED INC | 24.53 | 35.45B | ||
| DXCM | DEXCOM INC | 36.27 | 26.31B | ||
| PODD | INSULET CORP | 62.88 | 20.22B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.19 | 17.94B |
Related stock screener links
About AXGN
Company Profile
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 451 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
Company Info
AXOGEN INC
13631 Progress Blvd., Suite 400
Alachua FLORIDA 32615 US
CEO: Karen Zaderej
Employees: 452
Phone: 13864626817
AXOGEN INC / AXGN FAQ
What does AXGN do?
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 451 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
What is the stock price of AXOGEN INC today?
The current stock price of AXGN is 33.45 USD. The price increased by 1.98% in the last trading session.
Does AXOGEN INC pay dividends?
AXGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of AXGN stock?
AXGN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
On which exchange is AXGN stock listed?
AXGN stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for AXOGEN INC?
The Revenue of AXOGEN INC (AXGN) is expected to grow by 19.77% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
AXGN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AXGN. When comparing the yearly performance of all stocks, AXGN is one of the better performing stocks in the market, outperforming 97.71% of all stocks.
AXGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AXGN. AXGN has an average financial health and profitability rating.
AXGN Financial Highlights
Over the last trailing twelve months AXGN reported a non-GAAP Earnings per Share(EPS) of 0.29. The EPS increased by 2089670227099910400% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.97% | ||
| ROE | -1.74% | ||
| Debt/Equity | 0.4 |
AXGN Forecast & Estimates
15 analysts have analysed AXGN and the average price target is 37.13 USD. This implies a price increase of 11% is expected in the next year compared to the current price of 33.45.
For the next year, analysts expect an EPS growth of 127.99% and a revenue growth 19.77% for AXGN